Baker L - Search Results

1

Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).

LoRusso P, Foster BJ, Poplin E, McCormick J, Kraut M, Flaherty L, Heilbrun LK, Valdivieso M, Baker L. LoRusso P, et al. Among authors: baker l. Clin Cancer Res. 1995 Dec;1(12):1487-93. Clin Cancer Res. 1995. PMID: 9815948 Clinical Trial.

2

A dose-intensive regimen of 5-fluorouracil for the treatment of metastatic colorectal carcinoma.

Poplin EA, Kraut M, Baker L, Brodfuehrer J, Vaitkevicius V. Poplin EA, et al. Among authors: baker l. Cancer. 1991 Jan 15;67(2):367-71. doi: 10.1002/1097-0142(19910115)67:2<367::aid-cncr2820670209>3.0.co;2-2. Cancer. 1991. PMID: 1985732

3

Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study.

Poplin EA, Corbett T, Flaherty L, Tarasoff P, Redman BG, Valdivieso M, Baker L. Poplin EA, et al. Among authors: baker l. Invest New Drugs. 1992 Aug;10(3):165-70. doi: 10.1007/BF00877241. Invest New Drugs. 1992. PMID: 1428726 Clinical Trial.

4

Phase I trial of Adozelesin using the treatment schedule of daily x5 every 3 weeks.

Foster BJ, LoRusso PM, Poplin E, Zalupski M, Valdivieso M, Wozniak A, Flaherty L, Kasunic DA, Earhart RH, Baker LH. Foster BJ, et al. Among authors: baker lh. Invest New Drugs. 1996;13(4):321-6. doi: 10.1007/BF00873138. Invest New Drugs. 1996. PMID: 8824350 Clinical Trial.

5

Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1.

Foster BJ, Wiegand RA, LoRusso PM, Baker LH. Foster BJ, et al. Among authors: baker lh. Clin Cancer Res. 1995 Aug;1(8):831-7. Clin Cancer Res. 1995. PMID: 9816052

6

Colon cancer: medical therapy.

Poplin E, Baker L. Poplin E, et al. Among authors: baker l. Gastroenterol Clin North Am. 1988 Dec;17(4):873-86. Gastroenterol Clin North Am. 1988. PMID: 3068147 Review.

7

Response rates--an evolution.

Poplin E, Baker L. Poplin E, et al. Among authors: baker l. Cancer Chemother Pharmacol. 1994;34(4):361-3. doi: 10.1007/BF00686046. Cancer Chemother Pharmacol. 1994. PMID: 8033304

8

Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer.

Poplin EA, LoRusso P, Lokich JJ, Gullo JJ, Leming PD, Schulz JJ, Veach SR, McCulloch W, Baker L, Schein P. Poplin EA, et al. Among authors: baker l. Cancer Chemother Pharmacol. 1994;33(5):415-9. doi: 10.1007/BF00686271. Cancer Chemother Pharmacol. 1994. PMID: 8306416 Clinical Trial.

9

Identification and antitumor activity of a reduction product in the murine metabolism of pyrazoloacridine (NSC-366140).

Palomino E, Foster B, Kempff M, Corbett T, Wiegand R, Horwitz J, Baker L. Palomino E, et al. Among authors: baker l. Cancer Chemother Pharmacol. 1996;38(5):453-8. doi: 10.1007/s002800050510. Cancer Chemother Pharmacol. 1996. PMID: 8765439

10

Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients.

Chabot GG, Flaherty LE, Valdivieso M, Baker LH. Chabot GG, et al. Among authors: baker lh. Cancer Chemother Pharmacol. 1990;27(2):157-60. doi: 10.1007/BF00689102. Cancer Chemother Pharmacol. 1990. PMID: 2249333

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,003 results

Search Page

Filters